Investor Presentaiton

16 Commercial execution and innovation Diabetes care RybelsusⓇ is well-positioned in a competitive OAD market US OAD market is ~100 bDKK Positioning RybelsusⓇ earlier in the treatment cascade Novo NordiskⓇ Rybelsus® is capturing new patients in the modern OAD market -3% MOAD volume market growth 2% >90% of people starting on RybelsusⓇ are new to the GLP-1 class TRX share 35% Source of business for new to GLP-1 30% 39% 25% 76% 11% 13% 20% 49% 15% 54% 19% 8% 10% 11% 5% 13% 1% Patients 6% Value Metformin/Naïve DPP-4i 0% Oct SGLT-2i Other OADs 2019 Oral GLP-1 SGLT-2i DPP-4i Other OAD Insulin TRX: Total prescriptions; OAD: oral anti-diabetes medication; MOAD: Modern oral antidiabetes medication Source: Internal sales benchmark, CER; IQVIA, Xponent; IQVIA Nov'21-Feb'22 vs Aug'21-Nov'21 MOAD market growth 4% Feb 2022 ―sitagliptin empagliflozin Rybelsus CMD22 CAPITAL MARKETS DAY

View entire presentation